Cytosorbents (CTSO) Cash from Financing Activities (2010 - 2025)
Cytosorbents' (CTSO) quarterly Cash from Financing Activities came in at $2.5 million in Q4 2025, up 1383.83% on a YoY basis from $167000.0 in Q4 2024, and down 63.72% quarter-over-quarter from $6.8 million in Q1 2025.
Powered by 
Analysis
Cytosorbents (CTSO) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Cytosorbents (CTSO) has reported Cash from Financing Activities for 16 consecutive years, with $2.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 1383.83% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $9.3 million (changed 0.24% YoY), and the FY2025 full-year result was $9.3 million, changed 0.24% from the prior year.
- Cash from Financing Activities fell to $2.5 million in Q4 2025 per CTSO's latest filing, from $6.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $12.2 million in Q4 2023 and bottomed at -$571762.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $2.4 million across 5 years, with a median of $619020.5 in 2021.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 6278.64% in 2022, then slumped 183.56% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$80924.0 in 2021, then jumped by 6278.64% to $5.0 million in 2022, then surged by 144.21% to $12.2 million in 2023, then slumped by 98.63% to $167000.0 in 2024, then soared by 1383.83% to $2.5 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.5 million, $6.8 million, and $167000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 6.83 Mn |
| Dec 31, 2024 | 167,000.00 |
| Sep 30, 2024 | -99,000.00 |
| Jun 30, 2024 | 9.83 Mn |
| Mar 31, 2024 | -571,762.00 |
| Dec 31, 2023 | 12.21 Mn |
| Sep 30, 2023 | 648,323.00 |
| Jun 30, 2023 | 931,118.00 |
| Mar 31, 2023 | 684,283.00 |
| Dec 31, 2022 | 5.00 Mn |
| Mar 31, 2022 | -40,359.00 |
| Dec 31, 2021 | -80,924.00 |
| Sep 30, 2021 | 589,718.00 |
| Jun 30, 2021 | 129,852.00 |
| Mar 31, 2021 | 76,553.00 |
| Dec 31, 2020 | -15.15 Mn |
| Sep 30, 2020 | 56.38 Mn |
| Jun 30, 2020 | 7.23 Mn |
| Mar 31, 2020 | 17.88 Mn |